For instance, therapeutic effects of BTZ were studied in colon [115,116], prostate [117,118], breast [119,120], lung [121,122], melanoma [123,124], ovarian [20,125,126], myeloma [25,127,128], head and neck [20] cancers, EBV-associated lymphomas [129], hepatocellular carcinoma [130], and glioma [20,21]. The gene discussed is CASC3; the disease is plasma cell myeloma.